ASX-Dividend-Report-Banner

NABR Commends the IUCN's Decision to Reassess the Status of Long-Tailed Macaques

June 25, 2024 07:32 AM AEST | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 NABR Commends the IUCN's Decision to Reassess the Status of Long-Tailed Macaques
Image source: Kalkine Media

A Science-Based Approach Will Determine if the Species is Truly 'Endangered'

WASHINGTON, June 25, 2024 /PRNewswire/ -- The National Association for Biomedical Research (NABR) commends the Union for the Conservation of Nature (IUCN)'s decision to reassess the 'Endangered' designation of long-tailed macaque monkeys (macaca fascicularis).

"NABR is pleased that the IUCN will reassess its designation of long-tailed macaques as 'Endangered'," said Matthew R. Bailey, president of NABR. "The IUCN's decision to uplist long tailed macaques to 'Endangered' in 2022 was not justified, nor supported by scientific information. NABR looks forward to working with the IUCN to ensure the scientific integrity of its processes."

In 2023, NABR convened a technical review team to review the basis of the IUCN designation.1 In September 2023, NABR filed a formal petition with the IUCN followed by an expanded petition in February 2024. The expanded petition requested that the IUCN undertake a new science-based assessment of the species' status.

NABR's expanded petition demonstrates that the 2022 review by Hansen et. al., which the IUCN used as the basis for its decision to uplist the long-tailed macaque's status, misrepresents existing data.2

A separate petition filed by Dr. Hank Jenkins asserts that the Hansen et al. (2022) review authors possess conflicts of interest that require further investigation by the IUCN. This petition remains pending before the IUCN.

While the IUCN does not have any legislative or regulatory authority, its 'Red List' may influence policy decisions regarding the species. The IUCN's decision to reassess its 'Endangered' designation of long-tailed macaques is important because the species is used extensively in biomedical research.

Six of the 25 most used prescription drugs were developed with the help of long tailed macaques3. Research with long tailed macaques has also been crucial for advances in regenerative medicine4, immunology5, cancer6, vaccine development7, and pharmacology8.

The IUCN final ruling is available online at https://bit.ly/IUCNRulingLTMs.

More information regarding the NABR petition is available online at www.nabr.org.

About the National Association for Biomedical Research
Founded in 1979, the National Association for Biomedical Research (NABR) is the only 501(c)(6) nonprofit association dedicated to sound public policy for the humane use of animals in biomedical research, education, and testing. Members include more than 340 universities, medical and veterinary schools, teaching hospitals, pharmaceutical and biotechnology companies, patient groups, and academic and professional societies who rely on humane and responsible animal research to advance global human and animal health. Learn more about us at www.nabr.org.

1 Members of the NABR technical review team consist of Dr. Ray Hilborn, University of Washington; Dr. David Smith, formerly with the U.S. Geological Survey; and Dr. Robin Waples, University of Washington.

2 See Hilborn, R., & Smith, D. R. (2023). Is the long–tailed macaque at risk of extinction? American Journal of Primatology, e23590. https://doi.org/10.1002/ajp.23590

3 FBR's Role of LTMs in Research Fact Sheet 01-2024 FINAL, available online at https://fbr-cms-bucket.s3.us-west-1.amazonaws.com/FBR_s_Role_of_LT_Ms_in_Research_Fact_Sheet_01_2024_FINAL_802d17fd7d.pdf?updated_at=2024-02-26T16:44:17.000Z

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848615/#:~:text=Non%2Dhuman%20primates%20play%20a,organs%20affected%20by%20degenerative%20diseases. regenerative medicine

5 https://www.nature.com/articles/s41577-018-0005-7 immunology

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808758/#:~:text=Furthermore%2C%20NHP%20naturally%20develop%20cancers,and%20patients%20with%20human%20cancer. cancer research/therapies

7 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886327/ behavioral pharmacology

8 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402317/ COVID 19 vaccine development

Contact: Eva Maciejewski
[email protected]
(202) 967-8305

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.